Abstract
Summary: Optimizing coronary heart disease (CHD) risk reduction requires the application of clinical evidence to patient care, as well as the refinement of risk assessment. Clinical evidence indicates that most patients are not treated to optimal low‐density lipoprotein (LDL) cholesterol goals. Despite the efficacy of statin therapy in reducing the incidence of CHD, many treated patients still experience CHD events. Targeting other lipid factors such as high‐density lipoprotein cholesterol and triglycerides may augment the risk reduction achieved by lowering LDL cholesterol. Refined global risk assessment can lead to more accurate determinations of absolute risk and to the identification both of high‐risk patients needing aggressive intervention and intermediate‐risk patients who appear to be at low risk. Previous global risk assessment measures failed to identify a substantial proportion of primary prevention patients who would benefit from therapy. However, revised guidelines issued by the National Cholesterol Education Program introduce new criteria for more precise risk assessment and advocate use of the Framingham scoring system to calculate absolute risk. Although intensified treatment is recommended for high‐risk patients, cost considerations may limit drug therapy for some lower‐risk individuals.
Keywords: low‐density lipoprotein cholesterol, global risk assessment, statin therapy, coronary heart disease
Full Text
The Full Text of this article is available as a PDF (490.5 KB).
References
- 1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497 [DOI] [PubMed] [Google Scholar]
- 2. Pearson TA, Laurora I., Chu H., Kafonek S., The Lipid Treatment Assessment Project (L‐TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid‐lowering therapy and achieving low‐density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–467 [DOI] [PubMed] [Google Scholar]
- 3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015–3023 [PubMed] [Google Scholar]
- 4. Downs JR, Clearfield M., Weis S., Whittles E., Shapiro DR, Beere PA, Langendorfer A., Stein EA, Kruyer W., Gotto AM, for the AFCAPS/TexCAPS Research Group : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 5. The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
- 6. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L., Warnica W., Arnold JMO, Wun C‐C, Davis BR, Braunwald E., for the Cholesterol and Recurrent Events Trial Investigators : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
- 7. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994: 344: 1383–1389 [PubMed] [Google Scholar]
- 8. Shepherd J., Cobbe SM, Ford I., Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
- 9. Watts GF, Dimmitt SB: Fibrates: dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10: 561–574 [DOI] [PubMed] [Google Scholar]
- 10. The BIP Study Group : Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–27 [DOI] [PubMed] [Google Scholar]
- 11. Thompson GR, Barter PJ, Clinical lipidology at the end of the millennium. Curr Opin Lipidol 1999; 10: 521–526 [DOI] [PubMed] [Google Scholar]
- 12. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P., Oliver MF, Waters D., Zeiher A., Chaitman BR, Leslie S., Stern T., Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. J Am Med Assoc 2001: 285: 1711–1718 [DOI] [PubMed] [Google Scholar]
- 13. Wilson PWF, D'Agostino RB, Levy D., Belanger AM, Silbershatz H., Kannel WB, Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847 [DOI] [PubMed] [Google Scholar]
- 14. Second Joint Task Force of European and Other Societies on Coronary Prevention : Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J 1998: 19: 1434–1503 [DOI] [PubMed] [Google Scholar]
- 15. Gotto AM Jr., Whitney E., Stein EA, Shapiro DR, Clearfield M., Weis S., Jou JY, Langendörfer A., Beere PA, Watson DJ, Downs JR, de Cani JS, Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Eur Heart J 2000; 21: 1627–1633 [DOI] [PubMed] [Google Scholar]